相关实验视频

Updated: Jan 13, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

在外周动脉疾病中,HDL结构和功能的影响

Yu-Huang Liao¹, Semon Wu², Yu-Lin Ko^3,4,5

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231016, Taiwan.

|October 29, 2025

概括

高密度脂蛋白 (HDL) 结构,而不仅仅是水平,影响活动. 氧化HDL (Ox-HDL) 随着外周动脉疾病 (PAD) 的严重程度而增加,而HDL颗粒 (HDL-P) 和分数则减少,这表明它们在PAD中的作用.

科学领域:

心血管研究研究心血管研究
脂质代谢脂质代谢是什么
遗传学是一个遗传学.

背景情况:

高密度脂蛋白 (HDL) 颗粒的结构和功能对其活性至关重要,而不是度.
高密度胆固醇颗粒 (HDL-P) 在组成,大小和抗氧化功能方面呈现异质性.
周围动脉疾病 (PAD) 是一种复杂的疾病,受各种因素的影响,包括脂质状况.

研究的目的:

调查PAD患者的高密度脂蛋白,氧化高密度脂蛋白 (Ox-HDL) 和遗传决定因素之间的关系.
为了将HDL分数和Ox-HDL的水平与PAD严重程度相关联,用Rutherford尺度进行分类.
为了确定特定的单核酸多态 (SNPs),与PAD中改变的HDL概况相关.

主要方法:

招募PAD患者分层分成基于拉瑟福分类的组 (关节硬化严重程度和关键四肢缺血症).
量化高密度脂蛋白子部分,包括高密度脂蛋白颗粒 (HDL-P) 和小高密度脂蛋白颗粒 (S-HDL-P),以及氧化高密度脂蛋白 (Ox-HDL).
使用单核酸多态度 (SNP) 分析与HDL代谢和Ox-HDL水平相关的遗传关联.

主要成果:

氧化高密度脂蛋白 (Ox-HDL) 水平在患有关键肢体缺血症的患者中显著升高 (鲁瑟福II组).
在Rutherford II组中,HDL颗粒 (HDL-P),HDL胆固醇 (HDL-C) 和小HDL颗粒 (S-HDL-P) 的水平显著降低.
三个SNP (rs117685211,rs7934858,rs148877054) 显示了与HDL粒子和Ox-HDL的差异关联,特定的SNP与减少的HDL分数相关.

结论:

在患有外周动脉疾病 (PAD) 的患者中,HDL亚分和Ox-HDL水平显著改变.
这些发现突显了HDL结构和氧化状态的重要性,而不是仅仅是度,在PAD病变发生过程中.
特定的遗传变异可能会影响HDL颗粒的组成和氧化,导致PAD的发展.

关键词:

在HDL中,分数是HDL的分数.牛-HDLL 的使用.在 PAD PAD 里面,你会看到一些东西.在SNP中,SNP是SNP.

更多相关视频

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

A Modified Surgical Model of Hind Limb Ischemia in ApoE-/- Mice using a Miniature Incision

A Modified Surgical Model of Hind Limb Ischemia in ApoE-/- Mice using a Miniature Incision

Published on: May 13, 2021

相关概念视频

Peripheral Artery Disease I: Introduction

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...